

Urgent Field Safety Notice N. 01/2020

Product Name	List Number (LN)	Lot Number	Component Lot	Expiration Date
		80440	G0420	2020/05
Plasmaproteins Cal 3X	11206D	90372 H0400 20	2021/04	
	112000	90620	H0845	2021/08

Date: February 6th, 2020

Details on effected devices:

The purpose of this communication is to inform you that new HPT (Haptoglobin) and AGP (Alpha 1-Acid Glycoprotein) values have been assigned to the listed lots of REF 11206D Plasmaproteins Cal 3X.

Please review the information carefully and follow the reported actions.

Description of the problem:

Haptoglobin

Using the listed items for haptoglobin determination (REF 11050D) the analysis of results indicates a drift down vs primary standard for haptoglobin (ERM-DA470K/IFCC), resulting in an underestimation up to approximately 37% of the test results.

Alpha 1-Acid Glycoprotein

Using the listed items for Alpha 1-Acid Glycoprotein determination (REF 11135D) the analysis of results indicates a drift down vs primary standard for Alpha 1-Acid Glycoprotein (ERM-DA470K/IFCC), resulting in an underestimation up to approximately 12% of the test results.

Patient Impact:

Haptoglobin

The analysis of the data available for haptoglobin concluded that the use of the affected lots could generate falsely low haptoglobin results in patient samples that can incorrectly lead to a suspect of intravascular hemolysis. However, the assay results are not the sole basis for the physician medical decision, but require the evaluation of other parameters such as LDH, bilirubin and free Hb. Considering that the intra- and inter-individual variability is very wide (7.4% and 38% respectively) and the reference range is very large (30 - 200 mg/dL), only variations higher than 50% and haptoglobin results <30 mg/dL may have clinical significance. It must be noted also that any decision made by the physician will be done after evaluating the complete biochemical profile of the patient and according to the clinical history of the patient and other clinical findings.

Alpha 1-Acid Glycoprotein

The analysis of the data available for Alpha 1-Acid Glycoprotein concluded that the use of the affected lots could generate falsely low Alpha 1-Acid Glycoprotein results. Despite the bias introduced by the calibrator (12%) is almost the double of the desirable one (6,8%), Alpha 1-Acid Glycoprotein does play only an ancillary role in driving medical decisions and it is usually assessed together with CRP.



Actions to be taken:

Haptoglobin

• If the concerned REF 11206D Plasmaproteins Cal 3X kits have been distributed inside or outside the company, inform users of the updated haptoglobin values:

	F	Plasmaproteii Ref 1120 Haptoglo)6D	
Lot	Component Lot	Exp Date	New Value [mg/dL]	Previous Value [mg/dL]
80440	G0420	2020/05	322	224
90372	H0400	2021/04	298	213
90620	H0845	2021/08	304	225

- Inform users to perform a new calibration with the new haptoglobin assigned values.
- Since haptoglobin is present in the plasma in the acute phase of inflammatory processes, we suggest to evaluate with patient physician to contact only the patients reported with a value close to the low reference limit (30 mg/dL) and recently obtained without any other hemolysis marker available to support the haptoglobin result.
- Review the content of this communication with your Medical Director and retain this letter for your laboratory records.

Alpha 1-Acid Glycoprotein

• If the concerned REF 11206D Plasmaproteins Cal 3X kits have been distributed inside or outside the company, inform users of the updated Alpha 1-Acid Glycoprotein values:

	500	lasmaproteii Ref 1120 ha 1-Acid Gl)6D	
Lot	Component Lot	Exp Date	New Value [mg/dL]	Previous Value [mg/dL]
80440	G0420	2020/05	198	182
90372	H0400	2021/04	201	176
90620	H0845	2021/08	203	176

- Inform users to perform a new calibration with the new Alpha 1-Acid Glycoprotein assigned values.
- Review the content of this communication with your Medical Director and retain this letter for your laboratory records.

Transmission of this Field Safety Notice:

This notice needs to be passed on to all those who need to be aware within your organization or to any organization/individuals where the potentially affected devices have been transferred.



Reference person:

If you or any of your customers have any questions regarding this information, please contact your local area Customer Service.

Best regards







Urgent Field Safety Notice N. 02/2020

Product Name	List Number (LN)	Lot Number	Component Lot	Expiration Date	
		80440	G0420	2020/05	
Plasmaproteins Cal 3X	11206D	90372	H0400	2021/04	
		90620	H0845	2021/08	
Planara mateina Cal		80377	G0430	2020/05	
Plasmaproteins Cal	11200D	90362	H0420	2021/04	
	*	00440	G0551	2021/06	
		80412	G0552		
		00405	G0551	2021/06	
		90125	G0552		
		00000	G0551	2024/06	
Immuno Control Set	11211A	90308	G0552	2021/06	
		00500	H0813	2022/27	
		90598	H0814	2022/07	
	100	00670	H0813	2022/07	
		90679	H0814	2022/07	

Date: February 14th, 2020

Details on affected devices:

The purpose of this communication is to inform you that new HPT (Haptoglobin) and AGP (Alpha 1-Acid Glycoprotein) values have been assigned to the listed lots of REF 11206D Plasmaproteins Cal 3X, REF 11200D Plasmaproteins Cal and REF 11211A Immuno Control Set. Please review the information carefully and follow the actions reported.

Description of the problem:

Haptoglobin

Using the listed items for haptoglobin determination (REF 11050D) the analysis of results indicates a drift down vs primary standard for haptoglobin (ERM-DA470K/IFCC), resulting in an underestimation up to approximately 37% of the test results.

Alpha 1-Acid Glycoprotein

Using the listed items for Alpha 1-Acid Glycoprotein determination (REF 11135D) the analysis of results indicates a drift down vs primary standard for Alpha 1-Acid Glycoprotein (ERM-DA470K/IFCC), resulting in an underestimation up to approximately 12% of the test results.



Patient Impact:

Haptoglobin

The analysis of the data available for haptoglobin concluded that the use of the affected lots could generate falsely low haptoglobin results in patient samples that can incorrectly lead to a suspect of intravascular hemolysis. However, the assay results are not the sole basis for the physician medical decision, but require the evaluation of other parameters such as LDH, bilirubin and free Hb. Considering that the intra- and inter-individual variability is very wide (7.4% and 38% respectively) and the reference range is very large (30 - 200 mg/dL), only variations higher than 50% and haptoglobin results <30 mg/dL may have clinical significance. It must be noted also that any decision made by the physician will be done after evaluating the complete biochemical profile of the patient and according to the clinical history of the patient and other clinical findings.

Alpha 1-Acid Glycoprotein

The analysis of the data available for Alpha 1-Acid Glycoprotein concluded that the use of the affected lots could generate falsely low Alpha 1-Acid Glycoprotein results. Despite the bias introduced by the calibrator (12%) is almost the double of the desirable one (6.8%), Alpha 1-Acid Glycoprotein does play only an ancillary role in driving medical decisions and it is usually assessed together with CRP.

Actions to be taken:

Haptoglobin

 If the concerned REF 11206D Plasmaproteins Cal 3X, REF 11200D Plasmaproteins Cal and REF 11211A Immuno Control Set kits have been distributed inside or outside the company, inform users of the updated haptoglobin values:

Plasmaproteins Cal 3X Ref 11206D Haptoglobin					
Lot	Component Lot	Exp Date	New Value [mg/dL]	Previous Value [mg/dL]	
80440	G0420	2020/05	322	224	
90372	H0400	2021/04	298	213	
90620	H0845	2021/08	304	225	

		Plasmaprote	eins Cal		
		REF 112	00D		
Haptoglobin					
Lot	Component Lot	Exp Date	New Value [mg/dL]	Previous Value [mg/dL]	
80377	G0430	2020/05	154	112	
90362	H0420	2021/04	148	107	

Mod. 229e - rev. 2 - Data: 16/09/2015

SENTINEL

	Immuno Control Set REF 11211A Haptoglobine				
Lot	Component Lot	Exp Date	New Value [mg/dL]	Previous Value [mg/dL]	
90679	H0813 H0814	2022/07	71±18 220±55	52±13 159±40	
90598	H0813 H0814	2022/07	71±18 220±55	52±13 159±40	
90308	G0551 G0552	2021/06	56±14 159±40	42±10 120±30	
90125	G0551 G0552	2021/06	56±14 159±40	37±9 114±29	
80412	G0551 G0552	2021/06	56±14 159±40	37±9 114±29	

- Inform users to perform a new calibration with the new haptoglobin assigned values.
- Since haptoglobin is present in the plasma in the acute phase of inflammatory processes, we suggest to evaluate with patient physician to contact only the patients reported with a value close to the low reference limit (30 mg/dL) and recently obtained without any other hemolysis marker available to support the haptoglobin result.
- Review the content of this communication with your Medical Director and retain this letter for your laboratory records.

Alpha 1-Acid Glycoprotein

• If the concerned REF 11206D Plasmaproteins Cal 3X, REF 11200D Plasmaproteins Cal and REF 11211A Immuno Control Set kits have been distributed inside or outside the company, inform users of the updated Alpha 1-Acid Glycoprotein values:

	P	lasmaproteiı	ns Cal 3X	
		Ref 1120)6D	
	Alp	ha 1-Acid Gl	ycoprotein	
Lot	Component Lot	Exp Date	New Value [mg/dL]	Previous Value [mg/dL]
80440	G0420	2020/05	198	182
90372	H0400	2021/04	201	176
90620	H0845	2021/08	203	176

		Plasmaprote REF 1120	00D	
	Alp	ha 1-Acid Gl	ycoprotein	
Lot	Component lot	Exp Date	New Value [mg/dL]	Previous Value [mg/dL]
80377	G0430	2020/05	91*	91
90362	H0420	2021/04	85	88

^{*}Not modified from the previously assigned value.



	Immuno Control Set					
	REF 11211A					
	Alpha 1-Acid Glycoprotein					
Lot	Component	Exp Date	New Value	Previous Value		
LOC	lot	EXP Date	[mg/dL]	[mg/dL]		
80412	G0551	2021/06	41±10	37±9		
00712	G0552		126±32	114±29		
90125	G0551	2021/06	41±10	37±9		
30123	G0552	2021/00	126±32	114±29		
90308	G0551	2021/06	41±10	37±9		
90300	G0552	2021/00	126±32	114±29		
90598	H0813	2022/07	42±11	37±9		
90396	H0814	2022/07	131±33	119±30		
90679	H0813	2022/07	42±11	37±9		
300/3	H0814	2022/07	131±33	119±30		

- Inform users to perform a new calibration with the new Alpha 1-Acid Glycoprotein assigned values.
- Review the content of this communication with your Medical Director and retain this letter for your laboratory records.

Transmission of this Field Safety Notice:

This notice needs to be passed on to all those who need to be aware within your organization or to any organization/individuals where the potentially affected devices have been transferred.

Reference person:

If you or any of your customers have any questions regarding this information, please contact your local area Customer Service.

Best regards







Urgent Field Safety Notice N. 03/2020

Product Name	List Number (LN)	Lot Number	Component Lot	Expiration Date
		80440	G0420	2020/05
Plasmaproteins Cal 3X	11206D	90372	H0400	2021/04
		90620	H0845	2021/08
		90413	G0551	2024/06
		80412	G0552	2021/06
	00125	G0551	2021/06	
		90125	G0552	2021/06
Immuno Control Set	445445	00200	G0551	2021/06
Initialio Control Set	11211A	90308	G0552	2021/06
		00500	H0813	2022/07
		90598	H0814	2022/07
		00670	H0813	2022/07
		90679	H0814	2022/07

Date: February 15th, 2020

Details on affected devices:

The purpose of this communication is to inform you that new AAt (Alpha 1-Antitrypsin) and AGP (Alpha 1-Acid Glycoprotein) values have been assigned to the listed lots of REF 11206D Plasmaproteins Cal 3X and REF 11211A Immuno Control Set.

Please review the information carefully and follow the actions reported.

Description of the problem:

Alpha 1-Antitrypsin

Using the listed items for Alpha 1-Antitrypsin determination (REF 11012N) the analysis of results indicates a drift up vs primary standard for Alpha 1-Antitrypsin (ERM-DA470K/IFCC), resulting in an overestimation up to approximately 16% of the test results.

Alpha 1-Acid Glycoprotein

Using the listed items for Alpha 1-Acid Glycoprotein determination (REF 11135D) the analysis of results indicates a drift down vs primary standard for Alpha 1-Acid Glycoprotein (ERM-DA470K/IFCC), resulting in an underestimation up to approximately 12% of the test results.

Patient Impact:

Alpha 1-Antitrypsin

Alpha 1-antitrypsin (AAt) deficit causes important pulmonary and liver damages and has low intra- and inter-individual biological variation with a CV and Bias analytical quality specification of 3.0% and 4.3% respectively.

An overestimation in a patient affected by congenital deficit of the protein may mask the insufficiency and delay the diagnosis. However, these patients usually have very low AAt plasma concentration. In conclusion, an overestimation of 16% is not so relevant from the clinical point of view.



The analysis of the data available for Alpha 1-Acid Glycoprotein concluded that the use of the affected lots could generate falsely low Alpha 1-Acid Glycoprotein results. Despite the bias introduced by the calibrator (12%) is almost the double of the desirable one (6.8%), Alpha 1-Acid Glycoprotein does play only an ancillary role in driving medical decisions and it is usually assessed together with CRP.

Actions to be taken:

Alpha 1-Antitrypsin

 If the concerned REF 11206D Plasmaproteins Cal 3X and REF 11211A Immuno Control Set kits have been distributed inside or outside the company, inform users of the updated Alpha 1- Antitrypsin values:

		Plasmaproteii Ref 1120)6D	
		Alpha 1- Ant	itrypsin	
Lot	Component Lot	Exp Date	New Value [mg/dL]	Previous Value [mg/dL]
80440	G0420	2020/05	337	417
90372	H0400	2021/04	350	394
90620	H0845	2021/08	340	403

	Immuno Control Set REF 11211A						
		Alpha 1- Ant	itrypsin				
Lot	Component lot	Exp Date	New Value [mg/dL]	Previous Value [mg/dL]			
80412	G0551 G0552	2021/06	65±16 200±50	85±21 219±55			
90125	G0551 G0552	2021/06	65±16 200±50	85±21 219±55			
90308	G0551 G0552	2021/06	65±16 200±50	85±21 219±55			
90598	H0813 H0814	2022/07	64±16 212±53	78±19 239±60			
90679	H0813 H0814	2022/07	64±16 212±53	78±19 239±60			

- Inform users to perform a new calibration with the new Alpha 1- Antitrypsin assigned values.
- Review the content of this communication with your Medical Director and retain this letter for your laboratory records.



• If the concerned REF 11206D Plasmaproteins Cal 3X and REF 11211A Immuno Control Set kits have been distributed inside or outside the company, inform users of the updated Alpha 1-Acid Glycoprotein values:

	Plasmaproteins Cal 3X Ref 11206D Alpha 1-Acid Glycoprotein						
Lot	Component Lot	Exp Date	New Value [mg/dL]	Previous Value [mg/dL]			
80440	G0420	2020/05	198	182			
90372	H0400	2021/04	201	176			
90620	H0845	2021/08	203	176			

	Immuno Control Set REF 11211A Alpha 1-Acid Glycoprotein						
Lot	Component	Exp Date	New Value [mg/dL]	Previous Value [mg/dL]			
80412	G0551 G0552	2021/06	41±10 126±32	37±9 114±29			
90125	G0551 G0552	2021/06	41±10 126±32	37±9 114±29			
90308	G0551 G0552	2021/06	41±10 126±32	37±9 114±29			
90598	H0813 H0814	2022/07	42±11 131±33	37±9 119±30			
90679	H0813 H0814	2022/07	42±11 131±33	37±9 119±30			

- Inform users to perform a new calibration with the new Alpha 1-Acid Glycoprotein assigned values.
- Review the content of this communication with your Medical Director and retain this letter for your laboratory records.

Transmission of this Field Safety Notice:

This notice needs to be passed on to all those who need to be aware within your organization or to any organization/individuals where the potentially affected devices have been transferred.

Reference person:

If you or any of your customers have any questions regarding this information, please contact your local area Customer Service.

Best regards





Mod. 229e - rev. 2 - Data: 16/09/2015



Urgent Field Safety Notice N. 04/2020

Product Name	List Number (LN)	Lot Number	Component Lot	Expiration Date
		80440	G0420	2020/05
Plasmaproteins Cal 3X	11206D	90372	H0400	2021/04
		90620	H0845	2021/08
Dinampustaina Cal	44000	80377	G0430	2020/05
Plasmaproteins Cal	11200D	90362	H0420	2021/04

Date: February 14th, 2020

Details on affected devices:

The purpose of this communication is to inform you that new HPT (Haptoglobin), AAt (Alpha 1-Antitrypsin) and AGP (Alpha 1-Acid Glycoprotein) values have been assigned to the listed lots of REF 11206D Plasmaproteins Cal 3X and REF 11200D Plasmaproteins Cal. Please review the information carefully and follow the actions reported.

Description of the problem:

Haptoglobin

Using the listed items for haptoglobin determination (REF 11050D) the analysis of results indicates a drift down vs primary standard for haptoglobin (ERM-DA470K/IFCC), resulting in an underestimation up to approximately 37% of the test results.

Alpha 1-Acid Glycoprotein

Using the listed items for Alpha 1-Acid Glycoprotein determination (REF 11135D) the analysis of results indicates a drift down vs primary standard for Alpha 1-Acid Glycoprotein (ERM-DA470K/IFCC), resulting in an underestimation up to approximately 12% of the test results.

Alpha 1-Antitrypsin

Using the listed items for Alpha 1-Antitrypsin determination (REF 11012N) the analysis of results indicates a drift up vs primary standard for Alpha 1-Antitrypsin (ERM-DA470K/IFCC), resulting in an overestimation up to approximately 16% of the test results.

Patient Impact:

Haptoglobin

The analysis of the data available for haptoglobin concluded that the use of the affected lots could generate falsely low haptoglobin results in patient samples that can incorrectly lead to a suspect of intravascular hemolysis. However, the assay results are not the sole basis for the physician medical decision, but require the evaluation of other parameters such as LDH, bilirubin and free Hb. Considering that the intra- and inter-individual variability is very wide (7.4% and 38% respectively) and the reference range is very large (30 - 200 mg/dL), only variations higher than 50% and haptoglobin results <30 mg/dL may have clinical significance. It must be noted also that any decision made by the physician will be done after evaluating the complete biochemical profile of the patient and according to the clinical history of the patient and other clinical findings.

Mod. 229e - rev. 2 - Data: 16/09/2015



The analysis of the data available for Alpha 1-Acid Glycoprotein concluded that the use of the affected lots could generate falsely low Alpha 1-Acid Glycoprotein results. Despite the bias introduced by the calibrator (12%) is almost the double of the desirable one (6.8%), Alpha 1-Acid Glycoprotein does play only an ancillary role in driving medical decisions and it is usually assessed together with CRP.

Alpha 1- Antitrypsin

Alpha 1-Antitrypsin (AAt) deficit causes important pulmonary and liver damages and has low intra- and inter-individual biological variation with a CV and Bias analytical quality specification of 3.0% and 4.3% respectively.

An overestimation in a patient affected by congenital deficit of the protein may mask the insufficiency and delay the diagnosis. However, these patients usually have very low AAt plasma concentration. In conclusion, an overestimation of 16% is not so relevant from the clinical point of view.

Actions to be taken:

Haptoglobin

 If the concerned REF 11206D Plasmaproteins Cal 3X and REF 11200D Plasmaproteins Cal kits have been distributed inside or outside the company, inform users of the updated haptoglobin values:

	P	lasmaprotei Ref 1120		
		Haptoglo	obin	11 Sec. 11 70 11 11
Lot	Component Lot	Exp Date	New Value [mg/dL]	Previous Value [mg/dL]
80440	G0420	2020/05	322	224
90372	H0400	2021/04	298	213
90620	H0845	2021/08	304	225

	**	Plasmaprote REF 112		
	The Table	Haptoglo	bin	Luffe -
Lot	Component Lot	Exp Date	New Value [mg/dL]	Previous Value [mg/dL]
80377	G0430	2020/05	154	112
90362	H0420	2021/04	148	107

- Inform users to perform a new calibration with the new haptoglobin assigned values.
- Since haptoglobin is present in the plasma in the acute phase of inflammatory processes, we suggest to evaluate with patient physician to contact only the patients reported with a value close to the low reference limit (30 mg/dL) and recently obtained without any other hemolysis marker available to support the haptoglobin result.
- Review the content of this communication with your Medical Director and retain this letter for your laboratory records.



 If the concerned REF 11206D Plasmaproteins Cal 3X and REF 11200D Plasmaproteins Cal kits have been distributed inside or outside the company, inform users of the updated Alpha 1-Acid Glycoprotein values:

	P	Plasmaprotei Ref 1120		
	Alp	ha 1-Acid Gl	ycoprotein	
Lot	Component Lot	Exp Date	New Value [mg/dL]	Previous Value [mg/dL]
80440	G0420	2020/05	198	182
90372	H0400	2021/04	201	176
90620	H0845	2021/08	203	176

		Plasmaprote REF 112		
	Alp	ha 1-Acid Gl	ycoprotein	
Lot	Component	Exp Date	New Value [mg/dL]	Previous Value [mg/dL]
80377	G0430	2020/05	91*	91
90362	H0420	2021/04	85	88

^{*}Not modified from the previous assigned value.

- Inform users to perform a new calibration with the new Alpha 1-Acid Glycoprotein assigned values.
- Review the content of this communication with your Medical Director and retain this letter for your laboratory records.

Alpha 1- Antitrypsin

 If the concerned REF 11206D Plasmaproteins Cal 3X and REF 11200D Plasmaproteins Cal kits have been distributed inside or outside the company, inform users of the updated Alpha 1- Antitrypsin values:

	ŀ	Plasmaprotei Ref 1120		
		Alpha 1- Ant	itrypsin	
Lot	Component Lot	Exp Date	New Value [mg/dL]	Previous Value [mg/dL]
80440	G0420	2020/05	337	417
90372	H0400	2021/04	350	394
90620	H0845	2021/08	340	403

		Plasmaprote	eins Cal	
		REF 112	00D	
		Alpha 1- Ant	itrypsin	
Lot	Component lot	Exp Date	New Value [mg/dL]	Previous Value [mg/dL]
80377	G0430	2020/05	163	208
90362	H0420	2021/04	157	197



- Inform users to perform a new calibration with the new Alpha 1- Antitrypsin assigned values.
- Review the content of this communication with your Medical Director and retain this letter for your laboratory records.

Transmission of this Field Safety Notice:

This notice needs to be passed on to all those who need to be aware within your organization or to any organization/individuals where the potentially affected devices have been transferred.

Reference person:

If you or any of your customers have any questions regarding this information, please contact your local area Customer Service.

Best regards





Please kindly fill in the attached form and send it back to us as soon as possible via fax (n. +39 02 34551464) or e-mail (customerservice@sentinel.it).